Table 2.

Univariate and multivariate Cox regression analysis of clinicopathological factors influencing relapse-free survival in ER+, HER2−, node positive breast cancer patients

Variable	Univariate analysis			Multivariate analysis including ER:PR-B interactions			Multivariate analysis including ER:PR-B interactions and PR-B expression
	HR	95% CI	p Value	HR	95% CI	p Value	HR	95% CI	p Value
Age	1.002	0.979–1.026	0.835
T-stage pT2/3/4 vs pT1	3.383	1.214–9.427	0.020	3.031	1.063–8.649	0.038	3.209	1.128–9.130	0.029
N-stage pN2/3 vs pN1	1.999	1.122–3.561	0.019	1.623	0.890–2.961	0.114	1.536	0.842–2.802	0.162
Grade 2 vs 1	3.080	0.735–12.897	0.124
Grade 3 vs 1	1.804	0.862–3.774	0.117
Mitotic score 2 vs 1	1.139	0.574–2.261	0.710
Mitotic score 3 vs 1	1.175	0.801–1.724	0.408
Histology Lobular vs NST	1.448	0.678–3.091	0.339
Histology Other vs NST	1.433	0.722–2.841	0.304
Tumour number ≥2 vs 1	1.602	0.735–3.495	0.236
Mastectomy vs conservation	0.792	0.421–1.488	0.468
Axillary clearance vs sentinel node only	2.610	0.627–10.853	0.187
Adjuvant chemotherapy vs not	0.376	0.171–0.827	0.015	0.624	0.280–1.391	0.249	0.530	0.236–1.187	0.123
Adjuvant radiation vs not	0.740	0.3501.564	0.431
Adjuvant endocrine therapy vs not	0.305	0.129–0.720	0.007	0.299	0.116–0.767	0.012	0.374	0.146–0.954	0.040
Aromatase inhibitor vs tamoxifen	0.803	0.3861.669	0.557
PR expression Negative vs positive	2.028	1.100–3.731	0.024	1.543	0.789–3.021	0.205	1.220	0.619–2.404	0.566
PR-B expression Low vs high	3.636	1.543–8.621	0.003				2.841	1.134–7.143	0.026
ER:PR-B interactions low vs high	2.463	1.333–4.545	0.004	2.475	1.297–4.717	0.006	2.101	1.092–4.049	0.026

Clinical factors significant in the univariate analysis are included in the multivariate model. Bold indicates significant p values